GO BACKJanuary 29, 2020

News and Milestones



Shanghai Public Health Clinical Center (SPHCC) is using VivaLNK's continuous temperature sensor to combat the spread of Coronavirus in China. Working with VivaLNK solution partner, Yijing Health, the temperature sensor is applied directly onto the patient and allows for continuous, real time monitoring of changes in body temperature. More details in the link below.


111 Inc.

111, Inc. (NASDAQ:YI) enters into strategic partnership with Bestyoo to upgrade online healthcare service model. More details in link below.



Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center, New York, NY, discusses a phase Ia/Ib study (NCT02900716) exploring the synthetic lethality of the orally administered novel BTK inhibitor, dtrmwxhs-12 (DTRM-12), in combination with everolimus and pomalidomide (DTRM-555) in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL) or other B-cell lymphomas. Encouraging clinical activity was observed in several high-risk, multi-refractory CLL and lymphoma patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL. Link to interview below



BioNTech to acquire Neon to strengthen global leadership position in T cell therapies, further expanding the company's growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenes. Transaction expected to close in the second quarter of 2020. Link below.



December 9th, 2019, CARsgen Therapeutics received IND clearance from the NMPA for AB011 Humanized Claudin18.2 Monoclonal Antibody. Link below.

October, 28th, 2019, Carsgen announced investigational CAR-T therapy CT053 granted RMAT designation by the US FDA for R/R multiple myeloma. Link below



Yidu is China's Google of Healthcare, specializing in the consolidation, integration and interpretation of the massive medial data generated at top hospitals in China.


MicuRx has completed the US and China Phase II clinical trials with the report pending on their anti-superbug new antibiotic, which is a class 1.1 new drug in China.


Genova, in Q3 2015, signed a term sheet with a Swiss company on the technology licensing for one insulin product.


Cingular has completed clinical trials for its Dura Membrane product and expects to receive regulatory approval in late 2015; Cingular also began clinical trials for its tissue heart valve products in August 2015.


Allgens' breakthrough products were featured in Science Magazine and reported in the Nature Magazine. Allgens has maintained explosive growth in 2015. The year-on-year revenue growth rate is over 100%.


Jaguar Animal Health, Inc. announced its initial public offering of 2,860,000 shares of its common stock at a price to the public of $7.00 per share on 13 May 2015 (Nasdaq: JAGX).


Biocytogen's NSG mice are internationally recognized as the highest level of immune deficiency mice, which is best suited for human stem cell or tissue transplantation.